Total Payments
$122,210
2024 Payments
$3,667
Companies
30
Transactions
77
Medicare Patients
3,372
Medicare Billing
$963,731
Payment Breakdown by Category
Consulting$79,036 (64.7%)
Other$42,014 (34.4%)
Food & Beverage$838.43 (0.7%)
Education$321.81 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $79,036 | 21 | 64.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,814 | 9 | 34.2% |
| Food and Beverage | $838.43 | 36 | 0.7% |
| Education | $321.81 | 10 | 0.3% |
| Honoraria | $200.00 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Foundation Medicine, Inc. | $111,051 | 11 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $4,211 | 7 | $0 (2024) |
| Vertex Pharmaceuticals Incorporated | $1,050 | 2 | $0 (2022) |
| BeiGene USA, Inc. | $1,017 | 2 | $0 (2024) |
| GENZYME CORPORATION | $984.08 | 9 | $0 (2021) |
| GlaxoSmithKline, LLC. | $601.45 | 6 | $0 (2022) |
| Lantheus Medical Imaging, Inc. | $550.00 | 1 | $0 (2023) |
| Becton, Dickinson and Company | $508.33 | 1 | $0 (2023) |
| BeiGene, Ltd. | $500.00 | 1 | $0 (2023) |
| Halozyme Inc | $380.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,667 | 5 | AstraZeneca Pharmaceuticals LP ($2,745) |
| 2023 | $43,816 | 8 | Foundation Medicine, Inc. ($40,649) |
| 2022 | $1,316 | 4 | Vertex Pharmaceuticals Incorporated ($533.33) |
| 2021 | $1,493 | 9 | GENZYME CORPORATION ($700.00) |
| 2020 | $25,428 | 14 | Foundation Medicine, Inc. ($24,844) |
| 2019 | $22,055 | 31 | Foundation Medicine, Inc. ($21,268) |
| 2018 | $24,434 | 6 | Foundation Medicine, Inc. ($24,290) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/26/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 05/30/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Oncology | ||||||
| 05/16/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $516.67 | General |
| 04/25/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $25.43 | General |
| Category: Oncology | ||||||
| 01/06/2024 | Halozyme Inc | — | Consulting Fee | Cash or cash equivalent | $380.00 | General |
| 11/14/2023 | Lantheus Medical Imaging, Inc. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 10/24/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| Category: Oncology | ||||||
| 09/05/2023 | Daiichi Sankyo Inc. | — | Honoraria | Cash or cash equivalent | $200.00 | General |
| 08/25/2023 | Becton, Dickinson and Company | — | Consulting Fee | Cash or cash equivalent | $508.33 | General |
| 03/16/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2023 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 01/05/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device), FOUNDATIONONE LIQUID CDX | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $39,379.00 | General |
| Category: Oncology | ||||||
| 01/05/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device), FOUNDATIONONE LIQUID CDX | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,270.00 | General |
| Category: Oncology | ||||||
| 10/27/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 03/11/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $533.33 | General |
| 02/15/2022 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| 01/27/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $33.00 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2021 | GENZYME CORPORATION | CABLIVI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $350.00 | General |
| Category: Hematology | ||||||
| 10/20/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: ONCOLOGY | ||||||
| 07/21/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 07/01/2021 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $350.00 | General |
| 06/28/2021 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: BioOncology/Immunology | ||||||
| 06/02/2021 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $516.67 | General |
| 04/12/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 967 | 2,938 | $1.9M | $284,213 |
| 2022 | 11 | 1,134 | 3,008 | $1.8M | $272,202 |
| 2021 | 6 | 764 | 2,614 | $1.4M | $239,845 |
| 2020 | 4 | 507 | 1,995 | $815,049 | $167,470 |
Total Patients
3,372
Total Services
10,555
Medicare Billing
$963,731
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 255 | 1,192 | $853,675 | $150,132 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 225 | 882 | $586,626 | $74,351 | 12.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 156 | 412 | $205,869 | $22,580 | 11.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 75 | 75 | $69,102 | $11,599 | 16.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 41 | $30,868 | $5,328 | 17.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 47 | $17,296 | $5,065 | 29.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 113 | 177 | $46,197 | $4,844 | 10.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $20,495 | $3,427 | 16.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $11,355 | $2,344 | 20.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 28 | $7,560 | $2,014 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 21 | $15,054 | $1,765 | 11.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 23 | 27 | $7,047 | $765.18 | 10.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 208 | 708 | $541,844 | $90,709 | 16.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 222 | 865 | $539,204 | $72,565 | 13.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 192 | 660 | $305,274 | $37,382 | 12.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 121 | 245 | $90,160 | $22,577 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 91 | 91 | $82,364 | $15,453 | 18.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 47 | 48 | $32,970 | $8,549 | 25.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 25 | 25 | $25,100 | $4,159 | 16.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 22 | 31 | $27,352 | $4,137 | 15.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 73 | 139 | $36,279 | $3,912 | 10.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 42 | $29,904 | $3,776 | 12.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 28 | 42 | $10,794 | $2,696 | 25.0% |
| 99356 | Extended inpatient or observation hospital service, first hour | Facility | 2022 | 19 | 21 | $7,588 | $1,737 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 27 | $13,671 | $1,639 | 12.0% |
About Curtis Chong, MD, PHD
Curtis Chong, MD, PHD is a Internal Medicine healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1912167420.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Curtis Chong, MD, PHD has received a total of $122,210 in payments from pharmaceutical and medical device companies, with $3,667 received in 2024. These payments were reported across 77 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($79,036).
As a Medicare-enrolled provider, Chong has provided services to 3,372 Medicare beneficiaries, totaling 10,555 services with total Medicare billing of $963,731. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Medical Oncology
- Location Palo Alto, CA
- Active Since 06/10/2008
- Last Updated 04/28/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1912167420
Products in Payments
- FOUNDATIONONE LIQUID (Device) $57,377
- FOUNDATIONONE CDX (Device) $53,646
- LYNPARZA (Drug) $2,761
- IMFINZI (Biological) $1,388
- BRUKINSA (Drug) $1,000
- ZEJULA (Drug) $501.45
- CABLIVI (Biological) $350.00
- ELITEK (Drug) $284.08
- Vitrakvi (Drug) $124.23
- ERLEADA (Drug) $99.95
- JEVTANA (Drug) $99.95
- OPDIVO (Biological) $44.08
- TAGRISSO (Drug) $43.72
- IMBRUVICA (Drug) $37.16
- DARZALEX (Biological) $33.66
- FOUNDATIONONE (Device) $28.48
- PADCEV (Biological) $25.43
- IMLYGIC (Biological) $23.88
- MVASI (Biological) $23.47
- INJECTAFER (Drug) $23.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Palo Alto
Dr. Teck Ling, Md, MD
Internal Medicine — Payments: $900,598
Internal Medicine $900,598
Jennie Crews
Internal Medicine — Payments: $486,491
Internal Medicine $486,491
Byron Lee, Md, MD
Internal Medicine — Payments: $330,042
Internal Medicine $330,042
Bita Fakhri, M.d., M.p.h, M.D., M.P.H
Internal Medicine — Payments: $151,916
Internal Medicine $151,916
Dr. Richard Mamelok, M.d, M.D
Internal Medicine — Payments: $120,882
Internal Medicine $120,882
Millie Das, Md, MD
Internal Medicine — Payments: $105,357
Internal Medicine $105,357